STOCK TITAN

Blueprint Medicines to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
Blueprint Medicines Corporation (NASDAQ: BPMC) will host a live conference call and webcast on February 15, 2024, to report its fourth quarter and full year 2023 financial results and provide a corporate update. The call will be accessible via phone or webcast, with the archived webcast available for 30 days after the call.
Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass., Feb. 1, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, February 15, 2024, to report its fourth quarter and full year 2023 financial results and provide a corporate update.

To access the live conference call, please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to conference ID 071930. A webcast of the call will also be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at http://ir.blueprintmedicines.com/. The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call.

About Blueprint Medicines

Blueprint Medicines is a global precision therapy company that invents life-changing medicines. Applying an approach that is both precise and agile, we create therapies that selectively target the root cause of disease, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, we have brought our approved medicines to patients in the United States and Europe, and we are globally advancing multiple programs for mast cell disorders, including systemic mastocytosis and chronic urticaria, breast cancer and other solid tumors. For more information, visit www.BlueprintMedicines.com and follow us on X (formerly Twitter; @BlueprintMeds) and LinkedIn.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-to-report-fourth-quarter-and-full-year-2023-financial-results-on-thursday-february-15-2024-302043757.html

SOURCE Blueprint Medicines Corporation

Blueprint Medicines Corporation will host the live conference call and webcast on February 15, 2024.

The conference call and webcast will report Blueprint Medicines Corporation's fourth quarter and full year 2023 financial results and provide a corporate update.

To access the live conference call, please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to conference ID 071930.

A webcast of the call will be available under 'Events and Presentations' in the Investors & Media section of the Blueprint Medicines website at http://ir.blueprintmedicines.com/.

The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call.
Blueprint Medicines Corp

NASDAQ:BPMC

BPMC Rankings

BPMC Latest News

BPMC Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
US
Cambridge

About BPMC

blueprint medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. we are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. by focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. we see a substantial opportunity in kinase drug discovery and development